BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Shemi AG, Ashshi AM, Na Y, Li Y, Basalamah M, Al-Allaf FA, Oh E, Jung BK, Yun CO. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res 2016;35:74. [PMID: 27154307 DOI: 10.1186/s13046-016-0353-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Yun C, Hong J, Yoon A. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol 2022;13:953410. [DOI: 10.3389/fimmu.2022.953410] [Reference Citation Analysis]
2 Sajid M, Liu L, Sun C. The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front Immunol 2022;13:887186. [PMID: 35669776 DOI: 10.3389/fimmu.2022.887186] [Reference Citation Analysis]
3 Volovat S, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics 2022;14:397. [DOI: 10.3390/pharmaceutics14020397] [Reference Citation Analysis]
4 Senekal NS, Mahasa KJ, Eladdadi A, de Pillis L, Ouifki R. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model. Bull Math Biol 2021;83:75. [PMID: 34008149 DOI: 10.1007/s11538-021-00903-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
6 Diaz Arguello OA, Haisma HJ. Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers (Basel) 2021;13:1543. [PMID: 33801589 DOI: 10.3390/cancers13071543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang B, Wang X, Cheng P. Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses. Front Oncol 2020;10:561372. [PMID: 33680911 DOI: 10.3389/fonc.2020.561372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhang Y, Gao Y, Wei J, Gao Y. Dynamic Changes of Urine Proteome in Rat Models Inoculated with Two Different Hepatoma Cell Lines. J Oncol 2021;2021:8895330. [PMID: 33505467 DOI: 10.1155/2021/8895330] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Mirlekar B, Pylayeva-Gupta Y. IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers (Basel) 2021;13:E167. [PMID: 33418929 DOI: 10.3390/cancers13020167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
10 Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:137-49. [PMID: 32557715 DOI: 10.1002/hep.31424] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 23.0] [Reference Citation Analysis]
11 Jamieson TR, Poutou J, Ilkow CS. Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. Cytokine & Growth Factor Reviews 2020;56:102-14. [DOI: 10.1016/j.cytogfr.2020.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 2020;8:e001486. [PMID: 33046622 DOI: 10.1136/jitc-2020-001486] [Cited by in Crossref: 27] [Cited by in F6Publishing: 65] [Article Influence: 13.5] [Reference Citation Analysis]
13 Yoon AR, Jung BK, Choi E, Chung E, Hong J, Kim JS, Koo T, Yun CO. CRISPR-Cas12a with an oAd Induces Precise and Cancer-Specific Genomic Reprogramming of EGFR and Efficient Tumor Regression. Mol Ther 2020;28:2286-96. [PMID: 32682455 DOI: 10.1016/j.ymthe.2020.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Marotel M, Hasim MS, Hagerman A, Ardolino M. The two-faces of NK cells in oncolytic virotherapy. Cytokine Growth Factor Rev 2020;56:59-68. [PMID: 32586674 DOI: 10.1016/j.cytogfr.2020.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Ke C, Hou H, Li J, Su K, Huang C, Lin Y, Lu Z, Du Z, Tan W, Yuan Z. Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib. Cancers (Basel) 2020;12:E1157. [PMID: 32375399 DOI: 10.3390/cancers12051157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
16 Han J, Liu Q, Xu X, Qin W, Pan Y, Qin R, Zhao R, Gu Y, Gu J, Ren S. Relative Quantitation of Subclass-Specific Murine IgG Fc N-Glycoforms by Multiple Reaction Monitoring. ACS Omega 2020;5:8564-71. [PMID: 32337418 DOI: 10.1021/acsomega.9b04412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nguyen HM, Guz-Montgomery K, Saha D. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy. Cells 2020;9:E400. [PMID: 32050597 DOI: 10.3390/cells9020400] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
18 Redd Bowman KE, Lu P, Vander Mause ER, Lim CS. Advances in delivery vectors for gene therapy in liver cancer. Therapeutic Delivery 2020;11:833-50. [DOI: 10.4155/tde-2019-0076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
19 Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R, Chu X. Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front Oncol 2019;9:1182. [PMID: 31781493 DOI: 10.3389/fonc.2019.01182] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
20 Juengpanich S, Shi L, Iranmanesh Y, Chen J, Cheng Z, Khoo AK, Pan L, Wang Y, Cai X. The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review. Transl Oncol. 2019;12:1092-1107. [PMID: 31176993 DOI: 10.1016/j.tranon.2019.04.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
21 Du S, Liao S, Liu S, Xin Y. TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6. J Clin Transl Hepatol 2019;7:27-31. [PMID: 30944816 DOI: 10.14218/JCTH.2018.00055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Gupta V, Kalia N, Yadav M, Noyes A, Good J, Hendricks R, Xu W. Optimization and qualification of the single molecule array digital immunoassay for IL-12p70 in plasma of cancer patients. Bioanalysis 2018;10:1413-25. [DOI: 10.4155/bio-2018-0083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Kamil F, Rowe JH. How does the tumor microenvironment play a role in hepatobiliary tumors? J Gastrointest Oncol 2018;9:180-95. [PMID: 29564184 DOI: 10.21037/jgo.2017.06.09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
24 Lin CZ, Xiang GL, Zhu XH, Xiu LL, Sun JX, Zhang XY. Advances in the mechanisms of action of cancer-targeting oncolytic viruses. Oncol Lett 2018;15:4053-60. [PMID: 29541169 DOI: 10.3892/ol.2018.7829] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
25 Li Y, Sun R. Tumor immunotherapy: New aspects of natural killer cells. Chin J Cancer Res 2018;30:173-96. [PMID: 29861604 DOI: 10.21147/j.issn.1000-9604.2018.02.02] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
26 Sawahara H, Shiraha H, Uchida D, Kato H, Kato R, Oyama A, Nagahara T, Iwamuro M, Horiguchi S, Tsutsumi K, Mandai M, Mimura T, Wada N, Takeuchi Y, Kuwaki K, Onishi H, Nakamura S, Watanabe M, Sakaguchi M, Takaki A, Nouso K, Yagi T, Nasu Y, Kumon H, Okada H. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma: Novel Ad-REIC gene therapy for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2017;32:1769-77. [DOI: 10.1111/jgh.13757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
27 Mahasa KJ, Eladdadi A, de Pillis L, Ouifki R. Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. PLoS One 2017;12:e0184347. [PMID: 28934210 DOI: 10.1371/journal.pone.0184347] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
28 Li X, Zhang G, Chen Q, Lin Y, Li J, Ruan Q, Chen Y, Yu G, Wan X. CD317 Promotes the survival of cancer cells through apoptosis-inducing factor. J Exp Clin Cancer Res 2016;35:117. [PMID: 27444183 DOI: 10.1186/s13046-016-0391-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
29 El-Shemi AG, Ashshi AM, Na Y, Li Y, Basalamah M, Al-Allaf FA, Oh E, Jung BK, Yun CO. Erratum to: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res 2016;35:96. [PMID: 27316948 DOI: 10.1186/s13046-016-0365-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Huang XY, Huang ZL, Xu B, Chen Z, Re TJ, Zheng Q, Tang ZY, Huang XY. Elevated MTSS1 expression associated with metastasis and poor prognosis of residual hepatitis B-related hepatocellular carcinoma. J Exp Clin Cancer Res 2016;35:85. [PMID: 27230279 DOI: 10.1186/s13046-016-0361-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]